July - September 2009

September 11, 2009		Millennium Initiates Phase II Trial of Prostate Cancer Compound
September 10, 2009		Takeda Introduces 'Cisco TelePresence' (Advanced Videoconferencing System)
September 4, 2009		Takeda Receives FDA Complete Response Letter for the Investigational Fixed-Dose Combination of alogliptin and ACTOS® (pioglitazone HCl) for the Treatment of Type 2 Diabetes
September 3, 2009		Terumo and Takeda to Co-promote Takeda's Ethical Narcotic Formulations
September 3, 2009		Initiation of Pivotal Phase III Study with Catena®/Sovrima® (Idebenone) in Duchenne Muscular Dystrophy
August 28, 2009		Takeda Announces Changes in Management of Corporate Communications Dept. and Consumer Healthcare Company
August 28, 2009		Takeda Initiates Cardiovascular Outcomes Trial for Alogliptin, An Investigational Treatment for Type 2 Diabetes
July 27, 2009		Takeda Submits a New Drug Application for a Fixed-Dose Combination Tablet of Actos ® with sulfonylurea in Japan
July 27, 2009		Agreements Concluded for "SELTOUCH ® Pap 70, 140" Transdermal Absorption-type Analgesic and Anti-inflammatory Agent
July 23, 2009		Takeda Provides Update on the Investigational Fixed-Dose Combination of alogliptin and ACTOS® (pioglitazone HCl)
July 13, 2009		Notice Concerning the Determination of the Items of Stock Options (Stock Acquisition Rights) for Members of the Board of Directors
July 8, 2009		ENBREL to Add Indication of Juvenile Idiopathic Arthritis (JIA)
July 7, 2009		CBP501 Enters Phase II Trials for the Treatment of Non-Small Cell Lung Cancer
July 3, 2009		Takeda to hold the commencement ceremony for Construction of New Research Facilities